slCeMM1
slCeMM1 is a selective SLC16A3 (MCT4) inhibitor. slCeMM1 inhibits lactate transport, induces intracellular lactate accumulation, reduces viability of SLC16A3-dependent cells, and inhibits growth of SLC16A3-dependent cells. slCeMM1 can be used for the research of rheumatoid arthritis and cancer.
For research use only. We do not sell to patients.
- CAS No.: 949973-22-2
- Formula: C20H17F3N6O
- Molecular Weight:414.38
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
MCT4 |
In Vitro
slCeMM1 (serial dilutions; 72 h) potently and selectively inhibits viability of SLC16A3-dependent HAP1 SLC16A1-/- cells with an IC50 of 0.88 μM, while having no effect on HAP1 cells dependent on SLC16A1, SLC16A7, or SLC16A8[1].
slCeMM1 (serial dilutions; 6 h) induces intracellular lactate accumulation in SLC16A3-dependent HAP1 SLC16A1-/- cells with an IC50 of 91 nM, confirming inhibition of SLC16A3-mediated lactate export[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
CAS No. 949973-22-2
-
Molecular Weight 414.38
-
Formula C20H17F3N6O
-
SMILES
O=C(CCC1=C(C)N2N=C(C(F)(F)F)N=C2N=C1C)NC3=CN=C4C=CC=CC4=C3
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Collagen-Induced Arthritis
Collagen-induced arthritis (CIA) is an autoimmune murine model of rheumatoid arthritis in which immunization with type II collagen (CII) emulsified in an adjuvant induces a T cell- and autoantibody-driven inflammatory arthritis characterized by synovial hyperplasia, immune cell infiltration, and joint destruction. The model typically relies on genetically susceptible mouse strains (e. g. , DBA/1) and reproduces key features of human rheumatoid arthritis, including anti-collagen immune responses and progressive joint inflammation. Disease onset generally occurs within ~3-4 weeks after immunization, depending on antigen/adjuvant combinations and protocol variation. The immunopathology is driven by adaptive immune activation against CII, leading to systemic and local joint inflammation mediated by pro-inflammatory cytokines and effector immune cells, making CIA a standard preclinical platform for evaluating immunomodulatory and anti-arthritic interventions.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)